Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules (glycopyrronium / formoterol / budesonide) and Glenmark Airz FB Smartules (formoterol / budesonide) ampules for the treatment of COPD in India. According to the company, a clinical trial of nebulized Nebzmart GFB Smartules conducted in India demonstrated significant improvements in lung function.
Glenmark Pharmaceuticals President & Business Head, India Formulations, Alok Malik commented, “At Glenmark, innovation is about reimagining and redefining how therapies reach patients. With Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world’s first nebulized triple therapy for COPD, we are transforming respiratory care. This milestone reinforces Glenmark’s position as a front-runner in respiratory innovation and our commitment to making advanced, affordable, and accessible solutions for patients.”
Global Head of Clinical Development Monika Tandon said, “This launch represents a significant advancement in the management of COPD and demonstrates our focus in strengthening global respiratory leadership. Nebulizer medications are easy to use in patients with COPD. The strong efficacy and safety demonstrated in the clinical study further support this novel treatment approach in COPD.”
Read the Glenmark Pharmaceuticals press release
